Spots Global Cancer Trial Database for Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
Official Title: An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer After Prior Platinum Containing First Line Chemotherapy
Study ID: NCT00397293
Conditions
Study Description
Brief Summary: This is an open label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with topotecan in relapsed/refractory small cell lung cancer
Detailed Description: Further Study Details provided by Ascenta:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Birmingham, Alabama, United States
, Hot Springs, Arkansas, United States
, Loma Linda, California, United States
, Stamford, Connecticut, United States
, Jacksonville, Florida, United States
, Lake City, Florida, United States
, Boston, Massachusetts, United States
, Rochester, Minnesota, United States
, Lebanon, New Hampshire, United States
, High Point, North Carolina, United States
, Portland, Oregon, United States
, Columbia, South Carolina, United States
, Hilton Head Island, South Carolina, United States
, Germantown, Tennessee, United States
, Austin, Texas, United States
, Burlington, Vermont, United States
, Huntington, West Virginia, United States
Research Center (16), Russia, , Russian Federation
Research Centers (8), Ukraine, , Ukraine
Contact Details
Name: Lance Leopold, MD
Affiliation: Ascenta Therapeutics, Inc.
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
